Pharmacology of Chloroquine and Hydroxychloroquine

Browning, D., Pharmacology of Chloroquine and Hydroxychloroquine, 2014, 35-63, doi:10.1007/978-1-4939-0597-3_2, Apr 2014

Source

PDF

All
Studies

Meta
Analysis

HCQ for COVID-19

1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 423 studies, used in 59 countries.

Lower risk for mortality, hospitalization, progression, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,500+ studies for 121 treatments. c19hcq.org

Review of the pharmacology of CQ and HCQ. Some notable points:

- HCQ and CQ are equipotent but CQ is more toxic, the therapeutic ratio is higher for HCQ.
- Concentrations in different tissues can vary >10x, in particular the concentration in the lung is much higher in animal experiments.
- Tissue uptake as a function of dosage is nonlinear.

38 preclinical studies support the efficacy of HCQ for COVID-19:

11 In Silico studies1-11

24 In Vitro studies1,12-34

3 In Vivo animal studies16,26,35

Important missing comments or errors? Let us know.

1. González-Paz et al., Biophysical Analysis of Potential Inhibitors of SARS-CoV-2 Cell Recognition and Their Effect on Viral Dynamics in Different Cell Types: A Computational Prediction from In Vitro Experimental Data, ACS Omega, doi:10.1021/acsomega.3c06968.acs.org, doi.org.

2. Alkafaas et al., A study on the effect of natural products against the transmission of B.1.1.529 Omicron, Virology Journal, doi:10.1186/s12985-023-02160-6.biomedcentral.com, doi.org.

3. Guimarães Silva et al., Are Non-Structural Proteins From SARS-CoV-2 the Target of Hydroxychloroquine? An in Silico Study, ACTA MEDICA IRANICA, doi:10.18502/acta.v61i2.12533.kne-publishing.com, doi.org.

4. Nguyen et al., The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics, Bioinformatics and Biology Insights, doi:10.1177/11779322221149622.sagepub.com, doi.org.

5. Navya et al., A computational study on hydroxychloroquine binding to target proteins related to SARS-COV-2 infection, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2021.100714.sciencedirect.com, doi.org.

6. Yadav et al., Repurposing the Combination Drug of Favipiravir, Hydroxychloroquine and Oseltamivir as a Potential Inhibitor Against SARS-CoV-2: A Computational Study, Research Square, doi:10.21203/rs.3.rs-628277/v1.researchsquare.com, doi.org.

7. Hussein et al., Molecular Docking Identification for the efficacy of Some Zinc Complexes with Chloroquine and Hydroxychloroquine against Main Protease of COVID-19, Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.129979.sciencedirect.com, doi.org.

8. Baildya et al., Inhibitory capacity of Chloroquine against SARS-COV-2 by effective binding with Angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies, Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.129891.sciencedirect.com, doi.org.

9. Noureddine et al., Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: molecular docking and DFT calculations, Journal of King Saud University - Science, doi:10.1016/j.jksus.2020.101334.sciencedirect.com, doi.org.

10. Tarek et al., Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention, European Journal of Drug Metabolism and Pharmacokinetics, doi:10.1007/s13318-020-00640-6.springer.com, doi.org.

11. Rowland Yeo et al., Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1955.wiley.com, doi.org.

12. Hitti et al., Hydroxychloroquine attenuates double-stranded RNA-stimulated hyper-phosphorylation of tristetraprolin/ZFP36 and AU-rich mRNA stabilization, Immunology, doi:10.1111/imm.13835.wiley.com, doi.org.

13. Yan et al., Super-resolution imaging reveals the mechanism of endosomal acidification inhibitors against SARS-CoV-2 infection, ChemBioChem, doi:10.1002/cbic.202400404.wiley.com, doi.org.

14. Mohd Abd Razak et al., In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds, Natural Product Communications, doi:10.1177/1934578X231188861.sagepub.com, doi.org.

15. Alsmadi et al., The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel, AAPS PharmSciTech, doi:10.1208/s12249-023-02627-3.springer.com, doi.org.

16. Wen et al., Cholinergic α7 nAChR signaling suppresses SARS-CoV-2 infection and inflammation in lung epithelial cells, Journal of Molecular Cell Biology, doi:10.1093/jmcb/mjad048.oup.com, doi.org.

17. Kamga Kapchoup et al., In vitro effect of hydroxychloroquine on pluripotent stem cells and their cardiomyocytes derivatives, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1128382.frontiersin.org, doi.org.

18. Milan Bonotto et al., Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection, Antiviral Research, doi:10.1016/j.antiviral.2023.105655.sciencedirect.com, doi.org.

19. Miao et al., SIM imaging resolves endocytosis of SARS-CoV-2 spike RBD in living cells, Cell Chemical Biology, doi:10.1016/j.chembiol.2023.02.001.sciencedirect.com, doi.org.

20. Yuan et al., Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture, Communications Biology, doi:10.1038/s42003-022-03841-8.nature.com, doi.org.

21. Faísca et al., Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2, Pharmaceutics, doi:10.3390/pharmaceutics14040877.mdpi.com, doi.org.

22. Delandre et al., Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants, Pharmaceuticals, doi:10.3390/ph15040445.mdpi.com, doi.org.

23. Purwati et al., An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia, PLOS One, doi:10.1371/journal.pone.0252302.plos.org, doi.org.

24. Zhang et al., SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination, Cell Death & Differentiation, doi:10.1038/s41418-021-00782-3.nature.com, doi.org.

25. Dang et al., Structural basis of anti-SARS-CoV-2 activity of hydroxychloroquine: specific binding to NTD/CTD and disruption of LLPS of N protein, bioRxiv, doi:10.1101/2021.03.16.435741.biorxiv.org, doi.org.

26. Shang et al., Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice, Virology Journal, doi:10.1186/s12985-021-01515-1.biomedcentral.com, doi.org.

27. Wang et al., Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus, Phytomedicine, doi:10.1016/j.phymed.2020.153333.nih.gov, doi.org.

28. Sheaff, R., A New Model of SARS-CoV-2 Infection Based on (Hydroxy)Chloroquine Activity, bioRxiv, doi:10.1101/2020.08.02.232892.biorxiv.org, doi.org.

29. Ou et al., Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2, PLOS Pathogens, doi:10.1371/journal.ppat.1009212.plos.org, doi.org.

30. Andreani et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.sciencedirect.com, doi.org.

31. Clementi et al., Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro, Front. Microbiol., 10 July 2020, doi:10.3389/fmicb.2020.01704.frontiersin.org, doi.org.

32. Liu et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discovery 6, 16 (2020), doi:10.1038/s41421-020-0156-0.nature.com, doi.org.

33. Yao et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis., 2020 Mar 9, doi:10.1093/cid/ciaa237.oup.com, doi.org.

34. Wang (B) et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res. 30, 269–271, doi:10.1038/s41422-020-0282-0.nature.com, doi.org.

35. Shu-Han Lin et al., Inhalable Chitosan-Based Hydrogel as a Mucosal Adjuvant for Hydroxychloroquine in the Treatment for SARS-CoV-2 Infection in a Hamster Model, Journal of Microbiology, Immunology and Infection, doi:10.1016/j.jmii.2023.08.001.sciencedirect.com, doi.org.

Browning et al., 4 Apr 2014, peer-reviewed, 1 author.

This Paper HCQ All

Abstract: 2 Pharmacology of Chloroquine and Hydroxychloroquine Abbreviations 4AQR 4AQs ABW APC BCVA C CpG ODN CV CYP DFE DNA ERK FP GVF HC HIV HMG-CoA IBW IFN IL LD50 LDL M mRNA NG RA RNA RPE 4-Aminoquinoline retinopathy 4-Aminoquinolines (chloroquine and hydroxychloroquine) Actual body weight Antigen presenting cell Best corrected visual acuity Chloroquine CpG oligodeoxynucleotide Color vision Cytochrome P450 enzymes Dilated fundus examination Deoxyribonucleic acid Extracellular signal-regulated kinases Ferriprotoporphyrin IX Goldmann visual fields Hydroxychloroquine Human immunodeficiency virus 3-Hydroxy-3-methylglutarylcoenzyme A reductase Ideal body weight Interferon Interleukin Lethal dose 50 Low-density lipoprotein Mole Mitochondrial ribonucleic acid Not given Rheumatoid arthritis Ribonucleic acid Retinal pigment epithelium SARS SLE TLR TNF TNF-α V Severe acute respiratory syndrome Systemic lupus erythematosus Toll-like receptor Tumor necrosis factor Tumor necrosis factor α Volume of distribution This chapter covers the pharmacology of chloroquine and hydroxychloroquine, which is similar for both drugs [1], but the details are different. For example, both drugs are partially excreted in feces, but the proportions differ slightly—8–10 % for chloroquine and 15–24 % for hydroxychloroquine. Generally, whatever is said in this chapter about one drug can be assumed to apply to the other unless otherwise specified [1, 2]. Because both drugs are derivatives of a 4-aminoquinoline (4AQ) nucleus, they are referred to as 4AQs, and the retinopathy that they can cause is termed 4-aminoquinoline retinopathy (4AQR) [3]. Commonly used abbreviations in this chapter are collected in “Abbreviations” for reference. Each term will be first used in its full form, along with its abbreviation. 2.1 History In the 1600s, the Jesuits who proselytized Chile discovered from the Incas that the bark of the cinchona tree can cure malaria [4, 5]. Additional medicinal qualities of cinchona bark were described in the 1700s, and the British and Dutch transplanted these trees to Javan plantations in the early 1900s D.J. Browning, Hydroxychloroquine and Chloroquine Retinopathy, DOI 10.1007/978-1-4939-0597-3_2, © Springer Science+Business Media New York 2014 35 2 Pharmacology of Chloroquine and Hydroxychloroquine for the production of quinine. In 1894, Payne described the use of quinine to treat systemic lupus erythematosus (SLE) [6]. Other alkaloids contained in cinchona bark, such as pamaquine, were also successfully used to treat SLE [5]. When the Japanese army occupied Java in World War II, the natural supply of quinine was lost, and synthesis of antimalarials was pursued in the United States [7]. Quinacrine, a 9-aminoacridine compound, was first used, but had the unpleasant side effect of staining the skin and sclera yellow in a manner indistinguishable from icterus [8–10]. The 4AQs, chloroquine and hydroxychloroquine, were found to be effective as antimalarials and did not discolor the skin. Chloroquine was first synthesized in 1934 by Andersag of I.G. Farbenindustrie in a German effort to find drugs better than quinine [11]. The Germans lost interest in the drug when they judged it to be too toxic for use in man, but the Americans restudied the drug and found it to be effective against malaria and sufficiently safe [3, 7, 12]. Hydroxychloroquine was synthesized in 1946 and proposed as a safer alternative to chloroquine in 1955 [13]. Resistance to..

DOI record: { "DOI": "10.1007/978-1-4939-0597-3_2", "ISBN": [ "9781493905966", "9781493905973" ], "URL": "http://dx.doi.org/10.1007/978-1-4939-0597-3_2", "assertion": [ { "group": { "label": "Chapter History", "name": "ChapterHistory" }, "label": "First Online", "name": "first_online", "order": 1, "value": "4 April 2014" }, { "label": "Free to read", "name": "free", "value": "This content has been made available to all." } ], "author": [ { "affiliation": [], "family": "Browning", "given": "David J.", "sequence": "first" } ], "container-title": "Hydroxychloroquine and Chloroquine Retinopathy", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2014, 5, 9 ] ], "date-time": "2014-05-09T07:08:34Z", "timestamp": 1399619314000 }, "deposited": { "date-parts": [ [ 2023, 7, 13 ] ], "date-time": "2023-07-13T00:16:58Z", "timestamp": 1689207418000 }, "indexed": { "date-parts": [ [ 2024, 5, 10 ] ], "date-time": "2024-05-10T03:08:40Z", "timestamp": 1715310520984 }, "is-referenced-by-count": 91, "isbn-type": [ { "type": "print", "value": "9781493905966" }, { "type": "electronic", "value": "9781493905973" } ], "issued": { "date-parts": [ [ 2014 ] ] }, "language": "en", "license": [ { "URL": "http://www.springer.com/tdm", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2014, 1, 1 ] ], "date-time": "2014-01-01T00:00:00Z", "timestamp": 1388534400000 } } ], "link": [ { "URL": "http://link.springer.com/content/pdf/10.1007/978-1-4939-0597-3_2", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "page": "35-63", "prefix": "10.1007", "published": { "date-parts": [ [ 2014 ] ] }, "published-online": { "date-parts": [ [ 2014, 4, 4 ] ] }, "published-print": { "date-parts": [ [ 2014 ] ] }, "publisher": "Springer New York", "publisher-location": "New York, NY", "reference": [ { "author": "TW Bunch", "first-page": "161", "journal-title": "Mayo Clin Proc", "key": "2_CR1", "unstructured": "Bunch TW, O’Duffy JD. Disease modifying drugs for progressive rheumatoid arthritis. Mayo Clin Proc. 1980;55:161–79.", "volume": "55", "year": "1980" }, { "author": "AH Mackenzie", "first-page": "1", "journal-title": "Am J Med", "key": "2_CR2", "unstructured": "Mackenzie AH. Pharmacologic actions of 4-aminoquinoline compounds. Am J Med. 1983;75:1–7.", "volume": "75", "year": "1983" }, { "DOI": "10.1172/JCI101980", "author": "RW Berliner", "doi-asserted-by": "crossref", "first-page": "98", "journal-title": "J Clin Invest", "key": "2_CR3", "unstructured": "Berliner RW, Earle Jr DP, Taggart JV, Zubrod CG, Welch WJ, Conan NJ, Bauman E, Scudder ST, Shannon JA. Studies on the chemotherapy of the human malarias. VI. The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline. J Clin Invest. 1948;27:98–107.", "volume": "27", "year": "1948" }, { "DOI": "10.1007/978-3-7643-7726-7_5", "author": "B Bothwell", "doi-asserted-by": "crossref", "first-page": "81", "key": "2_CR4", "unstructured": "Bothwell B, Furst DE. Hydroxychloroquine. In: Day RO, Furst DE, editors. Antirheumatic therapy: actions and outcomes. Basel: Piet L.C.M. van Riel and Barry Bresnihan; 2005. p. 81–92.", "volume-title": "Antirheumatic therapy: actions and outcomes", "year": "2005" }, { "DOI": "10.1191/096120301678646092", "author": "DJ Wallace", "doi-asserted-by": "crossref", "first-page": "385", "journal-title": "Lupus", "key": "2_CR5", "unstructured": "Wallace DJ. Antimalarials-the ‘real’ advance in lupus. Lupus. 2001;10:385–7.", "volume": "10", "year": "2001" }, { "DOI": "10.1177/0961203393002001011", "author": "RI Rynes", "doi-asserted-by": "crossref", "first-page": "S1", "journal-title": "Lupus", "key": "2_CR6", "unstructured": "Rynes RI, Parke AL. Introduction to symposium on antimalarial therapy and lupus. Lupus. 1993;2:S1.", "volume": "2", "year": "1993" }, { "DOI": "10.1177/0961203396005001021", "author": "DJ Wallace", "doi-asserted-by": "crossref", "first-page": "S2", "journal-title": "Lupus", "key": "2_CR7", "unstructured": "Wallace DJ. The history of antimalarials. Lupus. 1996;5:S2–3.", "volume": "5", "year": "1996" }, { "DOI": "10.1093/rheumatology/36.7.799", "author": "RI Rynes", "doi-asserted-by": "crossref", "first-page": "799", "journal-title": "Br J Rheumatol", "key": "2_CR8", "unstructured": "Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol. 1997;36:799–805.", "volume": "36", "year": "1997" }, { "DOI": "10.1001/archderm.1959.01560230043008", "author": "HE Hobbs", "doi-asserted-by": "crossref", "first-page": "557", "journal-title": "Arch Dermatol.", "key": "2_CR9", "unstructured": "Hobbs HE, Calnan CD. Visual disturbances with antimalarial drugs, with particular reference to chloroquine keratopathy. Arch Dermatol. 1959;80:557–63.", "volume": "80", "year": "1959" }, { "DOI": "10.1016/0049-0172(78)90033-1", "author": "EL Dubois", "doi-asserted-by": "crossref", "first-page": "33", "journal-title": "Semin Arthritis Rheum", "key": "2_CR10", "unstructured": "Dubois EL. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum. 1978;8:33–51.", "volume": "8", "year": "1978" }, { "author": "EQ McChesney", "first-page": "3", "key": "2_CR11", "unstructured": "McChesney EQ, Fitch CD. 4-Aminoquinolines. In: Peters W, Richards WHG, editors. Antimalarial drugs II. Current antimalarials and new drug developments. Berlin: Springer; 1984. p. 3–60.", "volume-title": "Antimalarial drugs II. Current antimalarials and new drug developments", "year": "1984" }, { "key": "2_CR12", "unstructured": "Thompson PE, Webel LM. Antimalarial agents: chemistry and pharmacology. New York: Academic Press; 1972. p. 150–96." }, { "DOI": "10.1007/s10633-005-7349-6", "author": "R Tzekov", "doi-asserted-by": "crossref", "first-page": "111", "journal-title": "Doc Ophthalmol", "key": "2_CR13", "unstructured": "Tzekov R. Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. Doc Ophthalmol. 2005;110:111–20.", "volume": "110", "year": "2005" }, { "DOI": "10.1007/s12016-010-8243-x", "author": "I Ben-Zvi", "doi-asserted-by": "crossref", "first-page": "145", "journal-title": "Clin Rev Allergy Immunol.", "key": "2_CR14", "unstructured": "Ben-Zvi I, Kivity S, Langevitz P. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012;42:145–53.", "volume": "42", "year": "2012" }, { "DOI": "10.1097/00004397-198902930-00007", "author": "JR Lozier", "doi-asserted-by": "crossref", "first-page": "172", "journal-title": "Int Ophthalmol Clin", "key": "2_CR15", "unstructured": "Lozier JR, Friedlander MH. Complications of antimalarial therapy. Int Ophthalmol Clin. 1989;29:172–8.", "volume": "29", "year": "1989" }, { "DOI": "10.1182/blood-2008-03-144204", "author": "JH Rand", "doi-asserted-by": "crossref", "first-page": "1687", "journal-title": "Blood", "key": "2_CR16", "unstructured": "Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112:1687–95.", "volume": "112", "year": "2008" }, { "DOI": "10.1001/jama.1954.02940500010004", "author": "DM Pillsbury", "doi-asserted-by": "crossref", "first-page": "1330", "journal-title": "JAMA", "key": "2_CR17", "unstructured": "Pillsbury DM, Jacobson C. Treatment of chronic discoid lupus erythematosus with chloroquine (Aralen). JAMA. 1954;154:1330–3.", "volume": "154", "year": "1954" }, { "DOI": "10.1056/NEJM199101173240303", "author": "The Canadian Hydroxychloroquine Study Group", "doi-asserted-by": "crossref", "first-page": "150", "journal-title": "New Engl J Med", "key": "2_CR18", "unstructured": "The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. New Engl J Med. 1991;324:150–4.", "volume": "324", "year": "1991" }, { "DOI": "10.1111/j.1442-9071.1987.tb00097.x", "author": "CN Banks", "doi-asserted-by": "crossref", "first-page": "365", "journal-title": "Aust N Z Ophthalmol.", "key": "2_CR19", "unstructured": "Banks CN. Melanin: blackguard or red herring? Another look at chloroquine retinopathy. Aust N Z Ophthalmol. 1987;15:365–70.", "volume": "15", "year": "1987" }, { "DOI": "10.4269/ajtmh.1957.6.654", "author": "L Goldman", "doi-asserted-by": "crossref", "first-page": "654", "journal-title": "Am J Trop Med Hyg", "key": "2_CR20", "unstructured": "Goldman L, Preston RH. Reactions to chloroquine observed during the treatment of various dermatologic disorders. Am J Trop Med Hyg. 1957;6:654–7.", "volume": "6", "year": "1957" }, { "DOI": "10.1016/S0140-6736(59)90604-X", "author": "HE Hobbs", "doi-asserted-by": "crossref", "first-page": "478", "journal-title": "Lancet", "key": "2_CR21", "unstructured": "Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet. 1959;2:478–80.", "volume": "2", "year": "1959" }, { "DOI": "10.1097/00007611-199203000-00010", "author": "H Bernstein", "doi-asserted-by": "crossref", "first-page": "274", "journal-title": "South Med J", "key": "2_CR22", "unstructured": "Bernstein H. Ocular safety of hydroxychloroquine sulfate (Plaquenil). South Med J. 1992;85:274–9.", "volume": "85", "year": "1992" }, { "DOI": "10.1016/0002-9394(67)92518-4", "author": "RV Shearer", "doi-asserted-by": "crossref", "first-page": "245", "journal-title": "Am J Ophthalmol", "key": "2_CR23", "unstructured": "Shearer RV, Dubois EL. Ocular changes induced by long-term hydroxychloroquine (Plaquenil) therapy. Am J Ophthalmol. 1967;64:245–52.", "volume": "64", "year": "1967" }, { "DOI": "10.1038/nrrheum.2012.106", "author": "DJ Wallace", "doi-asserted-by": "crossref", "first-page": "522", "journal-title": "Nat Rev Rheumatol", "key": "2_CR24", "unstructured": "Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8:522–33.", "volume": "8", "year": "2012" }, { "DOI": "10.1016/j.ajo.2003.08.047", "author": "DJ Browning", "doi-asserted-by": "crossref", "first-page": "577", "journal-title": "Am J Ophthalmol", "key": "2_CR25", "unstructured": "Browning DJ. Bull’s-eye maculopathy associated with quinacrine therapy for malaria. Am J Ophthalmol. 2004;137:577–9.", "volume": "137", "year": "2004" }, { "key": "2_CR26", "unstructured": "Chloroquine. DrugBank: open data drug & drug target database. 2005. http://www.drugbank.ca/drugs/DB00608 . Accessed 22 Aug 2013." }, { "key": "2_CR27", "unstructured": "Hydroxychloroquine. DrugBank: open data drug & drug target database. 2007. http://www.drugbank.ca/drugs/DB01611 . Accessed 22 Aug 2013." }, { "author": "AM Potts", "first-page": "405", "journal-title": "Invest Ophthalmol", "key": "2_CR28", "unstructured": "Potts AM. The reaction of uveal pigment in vitro with polycyclic compounds. Invest Ophthalmol. 1964;3:405–16.", "volume": "3", "year": "1964" }, { "DOI": "10.1177/153537020422900704", "author": "SM Toler", "doi-asserted-by": "crossref", "first-page": "607", "journal-title": "Exp Biol Med", "key": "2_CR29", "unstructured": "Toler SM. Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy. Exp Biol Med. 2004;229:607–15.", "volume": "229", "year": "2004" }, { "DOI": "10.1034/j.1600-0463.2002.100606.x", "author": "SP Sundelin", "doi-asserted-by": "crossref", "first-page": "481", "journal-title": "APMIS.", "key": "2_CR30", "unstructured": "Sundelin SP, Terman A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS. 2002;110:481–9.", "volume": "110", "year": "2002" }, { "DOI": "10.1016/0006-2952(91)90006-Q", "author": "V Ferrari", "doi-asserted-by": "crossref", "first-page": "23", "journal-title": "Biochem Pharmacol", "key": "2_CR31", "unstructured": "Ferrari V, Cutler DJ. Kinetics and thermodynamics of chloroquine and hydroxychloroquine transport across the human erythrocyte membrane. Biochem Pharmacol. 1991;41:23–30.", "volume": "41", "year": "1991" }, { "DOI": "10.1001/archderm.1980.01640290097026", "author": "L Tanenbaum", "doi-asserted-by": "crossref", "first-page": "587", "journal-title": "Arch Dermatol", "key": "2_CR32", "unstructured": "Tanenbaum L, Tuffanelli DL. Antimalarial agents: chloroquine, hydroxychloroquine, and quinacrine. Arch Dermatol. 1980;116:587–91.", "volume": "116", "year": "1980" }, { "DOI": "10.1083/jcb.63.2.430", "author": "M Wibo", "doi-asserted-by": "crossref", "first-page": "430", "journal-title": "J Cell Biol", "key": "2_CR33", "unstructured": "Wibo M, Poole B. Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1. J Cell Biol. 1974;63:430–40.", "volume": "63", "year": "1974" }, { "DOI": "10.1038/235050a0", "author": "CA Homewood", "doi-asserted-by": "crossref", "first-page": "50", "journal-title": "Nature", "key": "2_CR34", "unstructured": "Homewood CA, Warhurst DC, Peters W, Baggaley VC. Lysosomes, pH, and anti-malarial action of chloroquine. Nature. 1972;235:50–2.", "volume": "235", "year": "1972" }, { "DOI": "10.1016/0006-2952(82)90612-8", "author": "KB Stepien", "doi-asserted-by": "crossref", "first-page": "3359", "journal-title": "Biochem Pharmacol", "key": "2_CR35", "unstructured": "Stepien KB, Wilczok T. Studies of the mechanism of chloroquine binding to synthetic dopa-melanin. Biochem Pharmacol. 1982;31:3359–65.", "volume": "31", "year": "1982" }, { "author": "JW Jailer", "first-page": "345", "journal-title": "J Pharmacol Exp Ther", "key": "2_CR36", "unstructured": "Jailer JW, Zubrod CG, Rosenfeld M, Shannon JA. Effect of acidosis and anoxia on the concentration of quinacrine and chloroquine in blood. J Pharmacol Exp Ther. 1948;92:345–51.", "volume": "92", "year": "1948" }, { "DOI": "10.1097/00007691-198907000-00001", "author": "EO Titus", "doi-asserted-by": "crossref", "first-page": "369", "journal-title": "Ther Drug Monit", "key": "2_CR37", "unstructured": "Titus EO. Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Ther Drug Monit. 1989;11:369–79.", "volume": "11", "year": "1989" }, { "DOI": "10.1111/j.1529-8019.2007.00131.x", "author": "S Kalia", "doi-asserted-by": "crossref", "first-page": "160", "journal-title": "Dermatol Ther", "key": "2_CR38", "unstructured": "Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther. 2007;20:160–74.", "volume": "20", "year": "2007" }, { "DOI": "10.3899/jrheum.111569", "author": "M Kishimoto", "doi-asserted-by": "crossref", "first-page": "1296", "journal-title": "J Rheumatol", "key": "2_CR39", "unstructured": "Kishimoto M, Deshpande GA, Yokogawa N, Buyon JP, Okada M. Use of hydroxychloroquine in Japan. J Rheumatol. 2012;39:1296–7.", "volume": "39", "year": "2012" }, { "DOI": "10.1191/0961203304lu514oa", "author": "R Araiza-Casillas", "doi-asserted-by": "crossref", "first-page": "119", "journal-title": "Lupus", "key": "2_CR40", "unstructured": "Araiza-Casillas R, Cardenas F, Morales Y, Cardiel MH. Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus. 2004;13:119–24.", "volume": "13", "year": "2004" }, { "DOI": "10.1016/S0049-0172(10)80009-5", "author": "M Easterbrook", "doi-asserted-by": "crossref", "first-page": "62", "journal-title": "Semin Arthritis Rheum", "key": "2_CR41", "unstructured": "Easterbrook M. The ocular safety of hydroxychloroquine. Semin Arthritis Rheum. 1993;23:62–7.", "volume": "23", "year": "1993" }, { "DOI": "10.1177/096120339600500313", "author": "IM Meinao", "doi-asserted-by": "crossref", "first-page": "237", "journal-title": "Lupus", "key": "2_CR42", "unstructured": "Meinao IM, Sato EI, Andrade LEC, Ferraz MB, Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus. 1996;5:237–41.", "volume": "5", "year": "1996" }, { "author": "F Akman", "first-page": "68", "journal-title": "Marmara Med J", "key": "2_CR43", "unstructured": "Akman F, Cerman E, Yenice O, Kazokoglu H. Two cases with chloroquine and hydroxychloroquine maculopathy. Marmara Med J. 2011;24:68–72.", "volume": "24", "year": "2011" }, { "DOI": "10.1191/0961203306lu2299oa", "author": "A Wozniacka", "doi-asserted-by": "crossref", "first-page": "268", "journal-title": "Lupus", "key": "2_CR44", "unstructured": "Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus. 2006;15:268–75.", "volume": "15", "year": "2006" }, { "author": "PR Bartel", "first-page": "32", "journal-title": "S Afr Med J", "key": "2_CR45", "unstructured": "Bartel PR, Roux P, Robinson E, Anderson IF, Brighton SW, Van der Hoven HJ, Becker PJ. Visual function and long-term chloroquine treatment. S Afr Med J. 1994;84:32–4.", "volume": "84", "year": "1994" }, { "DOI": "10.1007/s00417-011-1753-2", "author": "S Missner", "doi-asserted-by": "crossref", "first-page": "319", "journal-title": "Graefes Arch Clin Exp Ophthalmol.", "key": "2_CR46", "unstructured": "Missner S, Kellner U. Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography. Graefes Arch Clin Exp Ophthalmol. 2012;250:319–25.", "volume": "250", "year": "2012" }, { "DOI": "10.1016/0002-9343(88)90358-0", "author": "M Easterbrook", "doi-asserted-by": "crossref", "first-page": "23", "journal-title": "Am J Med", "key": "2_CR47", "unstructured": "Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med. 1988;85:23–9.", "volume": "85", "year": "1988" }, { "DOI": "10.1016/S0021-9258(18)38529-6", "author": "FS Parker", "doi-asserted-by": "crossref", "first-page": "897", "journal-title": "J Biol Chem", "key": "2_CR48", "unstructured": "Parker FS, Irvin JL. The interaction of chloroquine with nucleic acids and nucleoproteins. J Biol Chem. 1952;199:897–909.", "volume": "199", "year": "1952" }, { "DOI": "10.1211/0022357023141", "author": "M Tanaka", "doi-asserted-by": "crossref", "first-page": "463", "journal-title": "J Pharm Pharmacol", "key": "2_CR49", "unstructured": "Tanaka M, Ono C, Yamada M. Absorption, distribution and excretion of 14C-levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin-related radioactivity to melanin in vivo. J Pharm Pharmacol. 2004;56:463–9.", "volume": "56", "year": "2004" }, { "DOI": "10.1016/0006-2952(81)90021-6", "author": "H Tjalve", "doi-asserted-by": "crossref", "first-page": "1845", "journal-title": "Biochem Pharmacol", "key": "2_CR50", "unstructured": "Tjalve H, Nilsson M, Larsson B. Studies on the binding of chlorpromazine and chloroquine to melanin in vivo. Biochem Pharmacol. 1981;30:1845–7.", "volume": "30", "year": "1981" }, { "DOI": "10.1111/j.1600-0749.1993.tb00591.x", "author": "BS Larsson", "doi-asserted-by": "crossref", "first-page": "127", "journal-title": "Pigment Cell Res", "key": "2_CR51", "unstructured": "Larsson BS. Interaction between chemicals and melanin. Pigment Cell Res. 1993;6:127–44.", "volume": "6", "year": "1993" }, { "DOI": "10.1016/0006-2952(79)90326-5", "author": "B Larsson", "doi-asserted-by": "crossref", "first-page": "1181", "journal-title": "Biochem Pharmacol", "key": "2_CR52", "unstructured": "Larsson B, Tjalve H. Studies on the mechanism of drug-binding to melanin. Biochem Pharmacol. 1979;28:1181–7.", "volume": "28", "year": "1979" }, { "DOI": "10.1211/0022357022340", "author": "C Ono", "doi-asserted-by": "crossref", "first-page": "1647", "journal-title": "J Pharm Pharmacol", "key": "2_CR53", "unstructured": "Ono C, Yamada M, Tanaka M. Absorption, distribution and excretion of 14C-chloroquine after single oral administration in albino and pigmented rats: binding characteristics of chloroquine-related radioactivity to melanin in-vivo. J Pharm Pharmacol. 2003;55:1647–54.", "volume": "55", "year": "2003" }, { "DOI": "10.1211/0022357043932", "author": "M Tanaka", "doi-asserted-by": "crossref", "first-page": "977", "journal-title": "J Pharm Pharmacol", "key": "2_CR54", "unstructured": "Tanaka M, Takashina H, Tsutsumi S. Comparative assessment of ocular tissue distribution of drug-related radioactivity after chronic oral administration of C14-levofloxacin and C14-chloroquine in pigmented rats. J Pharm Pharmacol. 2004;56:977–83.", "volume": "56", "year": "2004" }, { "DOI": "10.1089/jop.1994.10.217", "author": "MM Salazar-Bookaman", "doi-asserted-by": "crossref", "first-page": "217", "journal-title": "J Ocul Pharmacol", "key": "2_CR55", "unstructured": "Salazar-Bookaman MM, Wainer I, Patil PN. Relevance of drug-melanin interactions to ocular pharmacology and toxicology. J Ocul Pharmacol. 1994;10:217–39.", "volume": "10", "year": "1994" }, { "DOI": "10.1006/rtph.1998.1243", "author": "B Leblanc", "doi-asserted-by": "crossref", "first-page": "124", "journal-title": "Regul Toxicol Pharmacol.", "key": "2_CR56", "unstructured": "Leblanc B, Jezequei S, Davies T, Hanton G, Taradach C. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol. 1998;28:124–32.", "volume": "28", "year": "1998" }, { "author": "L Feeney", "first-page": "583", "journal-title": "Invest Ophthalmol Vis Sci", "key": "2_CR57", "unstructured": "Feeney L. Lipofuscin and melanin of human retinal pigment epithelium. Fluorescence, enzyme cytochemical, and ultrastructural studies. Invest Ophthalmol Vis Sci. 1978;17:583–600.", "volume": "17", "year": "1978" }, { "DOI": "10.1016/0278-4327(91)90027-Y", "author": "M Boulton", "doi-asserted-by": "crossref", "first-page": "125", "journal-title": "Prog Retin Eye Res", "key": "2_CR58", "unstructured": "Boulton M. Ageing of the retinal pigment epithelium. Prog Retin Eye Res. 1991;11:125–51.", "volume": "11", "year": "1991" }, { "DOI": "10.1007/BF02307013", "author": "TA Ivanina", "doi-asserted-by": "crossref", "first-page": "32", "journal-title": "Graefes Arch Clin Exp Ophthalmol.", "key": "2_CR59", "unstructured": "Ivanina TA, Zueva MV, Lebedeva MN, Bogoslovsky AI, Bunin AJ. Ultrastructural alterations in rat and cat retina and pigment epithelium induced by chloroquine. Graefes Arch Clin Exp Ophthalmol. 1983;220:32–8.", "volume": "220", "year": "1983" }, { "author": "KM Gaafar", "first-page": "1231", "journal-title": "Arzneimittelforschung", "key": "2_CR60", "unstructured": "Gaafar KM, Abdel-Khalek LR, El-Sayed NK, Ramadan GA. Lipidemic effect as a manifestation of chloroquine retinotoxicity. Arzneimittelforschung. 1995;45:1231–5.", "volume": "45", "year": "1995" }, { "DOI": "10.1002/acr.20133", "author": "F Wolfe", "doi-asserted-by": "crossref", "first-page": "775", "journal-title": "Arthritis Care Res", "key": "2_CR61", "unstructured": "Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775–84.", "volume": "62", "year": "2010" }, { "DOI": "10.1001/archophthalmol.2011.371", "author": "MF Marmor", "doi-asserted-by": "crossref", "first-page": "461", "journal-title": "Arch Ophthalmol", "key": "2_CR62", "unstructured": "Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol. 2012;130:461–9.", "volume": "130", "year": "2012" }, { "author": "LM Gonasun", "first-page": "107", "journal-title": "Invest Ophthalmol Vis Sci", "key": "2_CR63", "unstructured": "Gonasun LM, Potts AM. In vitro inhibition of protein synthesis in the retinal pigment epithelium by chloroquine. Invest Ophthalmol Vis Sci. 1974;13:107–15.", "volume": "13", "year": "1974" }, { "DOI": "10.1080/15287397709529497", "author": "CG Mason", "doi-asserted-by": "crossref", "first-page": "977", "journal-title": "J Toxicol Environ Health.", "key": "2_CR64", "unstructured": "Mason CG. Ocular accumulation and toxicity of certain systemically administered drugs. J Toxicol Environ Health. 1977;2:977–95.", "volume": "2", "year": "1977" }, { "DOI": "10.2131/jts.1.32", "author": "Y Kasuya", "doi-asserted-by": "crossref", "first-page": "32", "journal-title": "J Toxicol Stud", "key": "2_CR65", "unstructured": "Kasuya Y, Miyata H, Watanabe M. Toxicological studies on the chloroquine-melanin affinity in vivo and in vitro in relation to chloroquine retinopathy. J Toxicol Stud. 1976;1:32–8.", "volume": "1", "year": "1976" }, { "author": "L Feeney-Burns", "first-page": "195", "journal-title": "Invest Ophthalmol Vis Sci", "key": "2_CR66", "unstructured": "Feeney-Burns L, Hilderbrand ES, Eldridge S. Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. Invest Ophthalmol Vis Sci. 1984;25:195–200.", "volume": "25", "year": "1984" }, { "DOI": "10.1016/S0049-0172(10)80011-3", "author": "J Iredale", "doi-asserted-by": "crossref", "first-page": "74", "journal-title": "Semin Arthritis Rheum", "key": "2_CR67", "unstructured": "Iredale J, Fieger H, Wainer IW. Determination of the stereoisomers of hydroxychloroquine and its major metabolites in plasma and urine following a single oral administration of racemic hydroxychloroquine. Semin Arthritis Rheum. 1993;23:74–81.", "volume": "23", "year": "1993" }, { "DOI": "10.2165/00003088-199631040-00003", "author": "J Ducharme", "doi-asserted-by": "crossref", "first-page": "257", "journal-title": "Clin Pharmacokinet", "key": "2_CR68", "unstructured": "Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 1996;31:257–74.", "volume": "31", "year": "1996" }, { "author": "IM Rollo", "first-page": "1045", "key": "2_CR69", "unstructured": "Rollo IM. Drugs used in the chemotherapy of malaria. In: Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. New York: Macmillan; 1975. p. 1045–68.", "volume-title": "The pharmacological basis of therapeutics", "year": "1975" }, { "DOI": "10.1111/j.1365-2125.1983.tb01532.x", "author": "LL Gustafsson", "doi-asserted-by": "crossref", "first-page": "471", "journal-title": "Br J Clin Pharmacol", "key": "2_CR70", "unstructured": "Gustafsson LL, Walker O, Alvan G, Beermann B, Estevez F, Gleisner L, Lindstrom B, Sjoqvist F. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol. 1983;15:471–9.", "volume": "15", "year": "1983" }, { "DOI": "10.1016/S0950-3579(05)80004-4", "author": "S Tett", "doi-asserted-by": "crossref", "first-page": "467", "journal-title": "Baillieres Clin Rheumatol", "key": "2_CR71", "unstructured": "Tett S, Cutler D, Day R. Antimalarials in rheumatic diseases. Baillieres Clin Rheumatol. 1990;4:467–89.", "volume": "4", "year": "1990" }, { "DOI": "10.3109/03009747409115809", "author": "AL Laaksonen", "doi-asserted-by": "crossref", "first-page": "103", "journal-title": "Scand J Rheumatol", "key": "2_CR72", "unstructured": "Laaksonen AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand J Rheumatol. 1974;3:103–8.", "volume": "3", "year": "1974" }, { "DOI": "10.1097/00124743-199804000-00004", "author": "DA Albert", "doi-asserted-by": "crossref", "first-page": "57", "journal-title": "J Clin Rheumatol", "key": "2_CR73", "unstructured": "Albert DA, Debois LKL, Lu KF. Antimalarial ocular toxicity, a critical appraisal. J Clin Rheumatol. 1998;4:57–62.", "volume": "4", "year": "1998" }, { "DOI": "10.1016/0002-9343(83)91265-2", "author": "EW McChesney", "doi-asserted-by": "crossref", "first-page": "11", "journal-title": "Am J Med", "key": "2_CR74", "unstructured": "McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med. 1983;75:11–8.", "volume": "75", "year": "1983" }, { "DOI": "10.1111/j.1365-2125.1988.tb05281.x", "author": "SE Tett", "doi-asserted-by": "crossref", "first-page": "303", "journal-title": "Br J Clin Pharmacol.", "key": "2_CR75", "unstructured": "Tett SE, Cutler DJ, Day RO, Brown KF. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1988;26:303–13.", "volume": "26", "year": "1988" }, { "DOI": "10.1007/BF00541305", "author": "SE Tett", "doi-asserted-by": "crossref", "first-page": "729", "journal-title": "Eur J Clin Pharmacol", "key": "2_CR76", "unstructured": "Tett SE, Cutler DJ. Apparent dose-dependence of chloroquine pharmacokinetics due to limited assay sensitivity and short sampling times. Eur J Clin Pharmacol. 1987;31:729–31.", "volume": "31", "year": "1987" }, { "DOI": "10.1002/art.10307", "author": "T Munster", "doi-asserted-by": "crossref", "first-page": "1460", "journal-title": "Arthritis Rheum", "key": "2_CR77", "unstructured": "Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, Lindsley H, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1460–9.", "volume": "46", "year": "2002" }, { "DOI": "10.3109/10428199709039008", "author": "KR Schultz", "doi-asserted-by": "crossref", "first-page": "201", "journal-title": "Leuk Lymphoma.", "key": "2_CR78", "unstructured": "Schultz KR, Gilman AL. The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. Leuk Lymphoma. 1997;24:201–10.", "volume": "24", "year": "1997" }, { "DOI": "10.4269/ajtmh.1977.26.1025", "author": "N Buchanan", "doi-asserted-by": "crossref", "first-page": "1025", "journal-title": "Am J Trop Med Hyg", "key": "2_CR79", "unstructured": "Buchanan N, Can der Walt LA. The binding of cloroquine to normal and kwashiorkor serum. Am J Trop Med Hyg. 1977;26:1025–7.", "volume": "26", "year": "1977" }, { "DOI": "10.1016/0002-9343(83)91269-X", "author": "AH Mackenzie", "doi-asserted-by": "crossref", "first-page": "40", "journal-title": "Am J Med", "key": "2_CR80", "unstructured": "Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med. 1983;75:40–5.", "volume": "75", "year": "1983" }, { "author": "SJ Katz", "first-page": "278", "journal-title": "Curr Eye Res", "key": "2_CR81", "unstructured": "Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Eye Res. 2011;23:278–81.", "volume": "23", "year": "2011" }, { "DOI": "10.1016/0002-9394(68)93868-3", "author": "T Lawwill", "doi-asserted-by": "crossref", "first-page": "530", "journal-title": "Am J Ophthalmol", "key": "2_CR82", "unstructured": "Lawwill T, Appleton B, Altstatt L. Chloroquine accumulation in human eyes. Am J Ophthalmol. 1968;65:530–2.", "volume": "65", "year": "1968" }, { "author": "A Goldstein", "key": "2_CR83", "unstructured": "Goldstein A, Aronow L, Kalman SM. Principles of drug action: the basis of pharmacology. New York: Wiley; 2013.", "volume-title": "Principles of drug action: the basis of pharmacology", "year": "2013" }, { "author": "M Rowland", "first-page": "579", "key": "2_CR84", "unstructured": "Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics. Concepts and applications. Philadelphia: Wolters Kluwer; 2011. p. 579.", "volume-title": "Clinical pharmacokinetics and pharmacodynamics. Concepts and applications", "year": "2011" }, { "DOI": "10.1001/archopht.1963.00960050476009", "author": "M Rubin", "doi-asserted-by": "crossref", "first-page": "474", "journal-title": "Arch Ophthalmol", "key": "2_CR85", "unstructured": "Rubin M, Bernstein H, Zvaifler NJ. Studies on the pharmacology of chloroquine. Recommendations for the treatment of chloroquine retinopathy. Arch Ophthalmol. 1963;70:474–81.", "volume": "70", "year": "1963" }, { "DOI": "10.1038/jid.1958.63", "author": "B Shaffer", "doi-asserted-by": "crossref", "first-page": "341", "journal-title": "J Invest Dermatol", "key": "2_CR86", "unstructured": "Shaffer B, Cahn MM, Levy EJ. Absorption of antimalarial drugs in human skin: spectroscopic and chemical analysis in epidermis and corium. J Invest Dermatol. 1958;30:341–5.", "volume": "30", "year": "1958" }, { "DOI": "10.1038/jid.2009.80", "author": "B Ramser", "doi-asserted-by": "crossref", "first-page": "2419", "journal-title": "J Invest Dermatol.", "key": "2_CR87", "unstructured": "Ramser B, Kokot A, Metze D, Weib N, Luger TA, Bohm M. Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts. J Invest Dermatol. 2009;129:2419–26.", "volume": "129", "year": "2009" }, { "DOI": "10.1136/jnnp.29.3.255", "author": "B Smith", "doi-asserted-by": "crossref", "first-page": "255", "journal-title": "J Neurol Neurosurg Psychiatry.", "key": "2_CR88", "unstructured": "Smith B, O’Grady F. Experimental chloroquine myopathy. J Neurol Neurosurg Psychiatry. 1966;29:255–8.", "volume": "29", "year": "1966" }, { "author": "D Projean", "first-page": "748", "journal-title": "Am Soc Pharmacol Exp Ther", "key": "2_CR89", "unstructured": "Projean D, Baune B, Farinotti R, Flinois JP, Beaune P, Taburet AM, Ducharme J. In vitro metabolism of chloroquine: Identification of CYP2cb, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Am Soc Pharmacol Exp Ther. 2003;31:748–54.", "volume": "31", "year": "2003" }, { "DOI": "10.1016/0006-2952(65)90295-9", "author": "MW Whitehouse", "doi-asserted-by": "crossref", "first-page": "1173", "journal-title": "Biochem Pharmacol", "key": "2_CR90", "unstructured": "Whitehouse MW, Bostrom H. Biochemical properties of anti-inflammatory drugs-VI. The effects of chloroquine (Resochin) and some of their potential metabolites on cartilage metabolism and oxidative phosphorylation. Biochem Pharmacol. 1965;14:1173–84.", "volume": "14", "year": "1965" }, { "author": "K Kuroda", "first-page": "156", "journal-title": "J Pharmacol Exp Ther", "key": "2_CR91", "unstructured": "Kuroda K. Detection and distribution of chloroquine metabolites in human tissues. J Pharmacol Exp Ther. 1962;137:156–61.", "volume": "137", "year": "1962" }, { "DOI": "10.1016/0002-9343(87)90444-X", "author": "ML Estes", "doi-asserted-by": "crossref", "first-page": "447", "journal-title": "Am J Med", "key": "2_CR92", "unstructured": "Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M, Shirey E, Ratliff NM. Chloroquine neuromyotoxicity. Clinical and pathological perspective. Am J Med. 1987;82:447–55.", "volume": "82", "year": "1987" }, { "DOI": "10.1007/BF02976712", "author": "KA Kim", "doi-asserted-by": "crossref", "first-page": "631", "journal-title": "Arch Pharm Res", "key": "2_CR93", "unstructured": "Kim KA, Park JY, Lee SJ, Lim S. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003;26:631–7.", "volume": "26", "year": "2003" }, { "DOI": "10.1007/s00296-004-0442-4", "author": "E Ben-Chetrit", "doi-asserted-by": "crossref", "first-page": "332", "journal-title": "Rheumatol Int", "key": "2_CR94", "unstructured": "Ben-Chetrit E, Tischel R, Hinz B, Levy M. The effects of colchicine and hydroxychloroquine on the cyclo-oxygenases COX-1 and COX-2. Rheumatol Int. 2005;25:332–5.", "volume": "25", "year": "2005" }, { "DOI": "10.1002/j.1552-4604.1987.tb03002.x", "author": "E Ette", "doi-asserted-by": "crossref", "first-page": "813", "journal-title": "J Clin Pharmacol", "key": "2_CR95", "unstructured": "Ette E, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol. 1987;27:813–6.", "volume": "27", "year": "1987" }, { "author": "HN Bernstein", "first-page": "292", "journal-title": "Ann Ophthalmol", "key": "2_CR96", "unstructured": "Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol. 1991;23:292–6.", "volume": "23", "year": "1991" }, { "DOI": "10.1016/0002-9343(83)91271-8", "author": "LA Runge", "doi-asserted-by": "crossref", "first-page": "52", "journal-title": "Am J Med", "key": "2_CR97", "unstructured": "Runge LA. Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis. Am J Med. 1983;75:52–6.", "volume": "75", "year": "1983" }, { "DOI": "10.1097/00007611-198810000-00033", "author": "WL Terrell III", "doi-asserted-by": "crossref", "first-page": "1327", "journal-title": "South Med J", "key": "2_CR98", "unstructured": "Terrell III WL, Haik KG, Haik Jr GM. Hydroxychloroquine sulfate and retinopathy. South Med J. 1988;81:1327–8.", "volume": "81", "year": "1988" }, { "DOI": "10.1002/art.1780200208", "author": "IL Dwosh", "doi-asserted-by": "crossref", "first-page": "685", "journal-title": "Arthritis Rheum", "key": "2_CR99", "unstructured": "Dwosh IL, Stein HB, Urowitz MB, Smythe HA, Hunter T, Ogryzlo MA. Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine. Arthritis Rheum. 1977;20:685–92.", "volume": "20", "year": "1977" }, { "DOI": "10.1002/art.1780130310", "author": "AH Mackenzie", "doi-asserted-by": "crossref", "first-page": "280", "journal-title": "Arthritis Rheum", "key": "2_CR100", "unstructured": "Mackenzie AH. An appraisal of chloroquine. Arthritis Rheum. 1970;13:280–91.", "volume": "13", "year": "1970" }, { "DOI": "10.1001/archopht.1982.01030030083006", "author": "DR Tobin", "doi-asserted-by": "crossref", "first-page": "81", "journal-title": "Arch Ophthalmol", "key": "2_CR101", "unstructured": "Tobin DR, Krohel G, Rynes RI. Hydroxychloroquine-seven-year experience. Arch Ophthalmol. 1982;100:81–3.", "volume": "100", "year": "1982" }, { "DOI": "10.1056/NEJM196308292690901", "doi-asserted-by": "crossref", "key": "2_CR223", "unstructured": "Henkind P, Rothfield NF. Ocular abnormalities in patients treated with synthetic antimalarial drugs. New Engl J Med. 1963;269:434–9." }, { "DOI": "10.1191/0961203302lu203ra", "author": "Y Molad", "doi-asserted-by": "crossref", "first-page": "356", "journal-title": "Lupus", "key": "2_CR102", "unstructured": "Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Weinberger A, Amit-Vazina M. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus. 2002;11:356–61.", "volume": "11", "year": "2002" }, { "DOI": "10.3899/jrheum.120572", "author": "PS Akhavan", "doi-asserted-by": "crossref", "first-page": "831", "journal-title": "J Rheumatol", "key": "2_CR103", "unstructured": "Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol. 2013;40:831–41.", "volume": "40", "year": "2013" }, { "DOI": "10.1002/art.1780050105", "author": "E Scull", "doi-asserted-by": "crossref", "first-page": "30", "journal-title": "Arthritis Rheum", "key": "2_CR104", "unstructured": "Scull E. Chloroquine and hydroxychloroquine therapy in rheumatoid arthritis. Arthritis Rheum. 1962;5:30–6.", "volume": "5", "year": "1962" }, { "author": "AW Bagnall", "first-page": "182", "journal-title": "Can Med Assoc J", "key": "2_CR105", "unstructured": "Bagnall AW. The value of chloroquine in rheumatoid disease. A four year study of continuous therapy. Can Med Assoc J. 1957;77:182–94.", "volume": "77", "year": "1957" }, { "DOI": "10.1016/0002-9343(83)91211-1", "author": "EM Adams", "doi-asserted-by": "crossref", "first-page": "321", "journal-title": "Am J Med", "key": "2_CR106", "unstructured": "Adams EM, Yocum DE, Bell CL. Hydroxychloroquine in the treatment of rheumatoid arthritis. Am J Med. 1983;75:321–6.", "volume": "75", "year": "1983" }, { "DOI": "10.1097/00000441-195322510-00012", "author": "GG Haydu", "doi-asserted-by": "crossref", "first-page": "71", "journal-title": "Am J Med Sci", "key": "2_CR107", "unstructured": "Haydu GG. Rheumatoid arthritis therapy: a rationale and the use of chloroquine diphosphate. Am J Med Sci. 1953;225:71–5.", "volume": "225", "year": "1953" }, { "DOI": "10.1191/096120398678919778", "author": "E Tsakonas", "doi-asserted-by": "crossref", "first-page": "80", "journal-title": "Lupus", "key": "2_CR108", "unstructured": "The Canadian Hydroxychloroquine Study Group, Tsakonas E, Joseph L, Esdaile JM, Choquette D, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus. 1998;7:80–5.", "volume": "7", "year": "1998" }, { "DOI": "10.7326/0003-4819-119-11-199312010-00002", "author": "P Clark", "doi-asserted-by": "crossref", "first-page": "1067", "journal-title": "Ann Intern Med.", "key": "2_CR109", "unstructured": "Clark P, Cases E, Tugwell R, Medina C, Gheno C, Tenorio G, Orozco JA. Hydroxychloroquine compared with placebo in rheumatoid arthritis. Ann Intern Med. 1993;119:1067–71.", "volume": "119", "year": "1993" }, { "DOI": "10.1016/0049-0172(87)90023-0", "author": "W Maksymowych", "doi-asserted-by": "crossref", "first-page": "206", "journal-title": "Semin Arthritis Rheum", "key": "2_CR110", "unstructured": "Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum. 1987;16:206–21.", "volume": "16", "year": "1987" }, { "DOI": "10.1136/ard.15.3.251", "author": "A Freedman", "doi-asserted-by": "crossref", "first-page": "251", "journal-title": "Ann Rheum Dis", "key": "2_CR111", "unstructured": "Freedman A. Chloroquine and rheumatoid arthritis. A short-term controlled trial. Ann Rheum Dis. 1956;15:251–7.", "volume": "15", "year": "1956" }, { "DOI": "10.1016/0002-9343(83)91268-8", "author": "RI Rynes", "doi-asserted-by": "crossref", "first-page": "35", "journal-title": "Am J Med", "key": "2_CR112", "unstructured": "Rynes RI. Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. Am J Med. 1983;75:35–9.", "volume": "75", "year": "1983" }, { "DOI": "10.1016/S0002-9394(02)01392-2", "author": "DJ Browning", "doi-asserted-by": "crossref", "first-page": "649", "journal-title": "Am J Ophthalmol", "key": "2_CR113", "unstructured": "Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol. 2002;133:649–56.", "volume": "133", "year": "2002" }, { "author": "C Wang", "first-page": "808", "journal-title": "J Rheumatol", "key": "2_CR114", "unstructured": "Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol. 1999;26:808–15.", "volume": "26", "year": "1999" }, { "DOI": "10.1136/ard.41.Suppl_1.26", "author": "HE Paulus", "doi-asserted-by": "crossref", "first-page": "26", "journal-title": "Ann Rheum Dis", "key": "2_CR115", "unstructured": "Paulus HE. An overview of benefit/risk of disease modifying treatment of rheumatoid arthritis as of today. Ann Rheum Dis. 1982;41:26–9.", "volume": "41", "year": "1982" }, { "DOI": "10.1136/ard.2006.068676", "author": "GS Alarcon", "doi-asserted-by": "crossref", "first-page": "1168", "journal-title": "Ann Rheum Dis", "key": "2_CR116", "unstructured": "Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, Vila LM, Reveille JD. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168–72.", "volume": "66", "year": "2007" }, { "DOI": "10.1177/0961203396005001031", "author": "R Fox", "doi-asserted-by": "crossref", "first-page": "S4", "journal-title": "Lupus", "key": "2_CR117", "unstructured": "Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus. 1996;5:S4–10.", "volume": "5", "year": "1996" }, { "DOI": "10.1517/14740338.2011.566555", "author": "C Abarientos", "doi-asserted-by": "crossref", "first-page": "705", "journal-title": "Expert Opin Drug Saf", "key": "2_CR118", "unstructured": "Abarientos C, Sperber K, Shapiro DL, Aronow WS, Chao CP, Ash JY. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. Expert Opin Drug Saf. 2011;10:705–14.", "volume": "10", "year": "2011" }, { "DOI": "10.1002/art.1780390502", "author": "American College of Rheumatology Ad Hoc Committee on Clinical Guidelines", "doi-asserted-by": "crossref", "first-page": "713", "journal-title": "Arthritis Rheum", "key": "2_CR119", "unstructured": "American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 1996;39:713–22.", "volume": "39", "year": "1996" }, { "DOI": "10.1002/1529-0131(199902)42:2<357::AID-ANR19>3.0.CO;2-J", "author": "DE Furst", "doi-asserted-by": "crossref", "first-page": "357", "journal-title": "Arthritis Rheum", "key": "2_CR120", "unstructured": "Furst DE, Lindsley H, Baethge B, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, McLaughlin GE, Moreland LW, et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis. Arthritis Rheum. 1999;42:357–65.", "volume": "42", "year": "1999" }, { "DOI": "10.1002/jps.20792", "author": "AM Kaufmann", "doi-asserted-by": "crossref", "first-page": "729", "journal-title": "J Pharm Sci.", "key": "2_CR121", "unstructured": "Kaufmann AM, Krise JP. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci. 2007;96:729–46.", "volume": "96", "year": "2007" }, { "DOI": "10.3109/03009747609165456", "author": "A Elman", "doi-asserted-by": "crossref", "first-page": "161", "journal-title": "Scand J Rheumatol", "key": "2_CR122", "unstructured": "Elman A, Gullberg R, Nillson E, Rendahl I, Wachtmeister L. Choroquine retinopathy in patients with rheumatoid arthritis. Scand J Rheumatol. 1976;5:161–6.", "volume": "5", "year": "1976" }, { "DOI": "10.1136/bjo.53.2.101", "author": "SPB Percival", "doi-asserted-by": "crossref", "first-page": "101", "journal-title": "Br J Ophthalmol.", "key": "2_CR123", "unstructured": "Percival SPB, Behrman J. Ophthalmological safety of chloroquine. Br J Ophthalmol. 1969;53:101–9.", "volume": "53", "year": "1969" }, { "DOI": "10.1136/ard.56.3.188", "author": "DJ Grierson", "doi-asserted-by": "crossref", "first-page": "188", "journal-title": "Ann Rheum Dis", "key": "2_CR124", "unstructured": "Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis. 1997;56:188–90.", "volume": "56", "year": "1997" }, { "DOI": "10.1016/j.ajo.2012.09.025", "author": "DJ Browning", "doi-asserted-by": "crossref", "first-page": "418", "journal-title": "Am J Ophthalmol", "key": "2_CR125", "unstructured": "Browning DJ. Impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;155:418–28.", "volume": "155", "year": "2013" }, { "DOI": "10.1016/j.ajo.2013.04.011", "author": "DJ Browning", "doi-asserted-by": "crossref", "first-page": "410", "journal-title": "Am J Ophthalmol", "key": "2_CR126", "unstructured": "Browning DJ. Reply to impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;156:410–1.", "volume": "156", "year": "2013" }, { "DOI": "10.1136/ard.51.12.1318", "author": "EF Morand", "doi-asserted-by": "crossref", "first-page": "1318", "journal-title": "Ann Rheum Dis", "key": "2_CR127", "unstructured": "Morand EF, McCloud PI, Littlejohn GO. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 1992;51:1318–21.", "volume": "51", "year": "1992" }, { "DOI": "10.1177/0961203396005001051", "author": "M Petri", "doi-asserted-by": "crossref", "first-page": "S16", "journal-title": "Lupus", "key": "2_CR128", "unstructured": "Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5:S16–22.", "volume": "5", "year": "1996" }, { "DOI": "10.1016/S0140-6736(68)91336-6", "author": "LJ Bruce-Chwatt", "doi-asserted-by": "crossref", "first-page": "1039", "journal-title": "Lancet", "key": "2_CR129", "unstructured": "Bruce-Chwatt LJ. Chloroquine blindness? Lancet. 1968;2:1039.", "volume": "2", "year": "1968" }, { "author": "H Reed", "first-page": "176", "journal-title": "Can Med Assoc J.", "key": "2_CR130", "unstructured": "Reed H, Campbell AA. Central scotomata following chloroquine therapy. Can Med Assoc J. 1962;86:176–8.", "volume": "86", "year": "1962" }, { "DOI": "10.1097/IEB.0b013e318220f383", "author": "M Easterbrook", "doi-asserted-by": "crossref", "first-page": "132", "journal-title": "Evid Based ophthalmol.", "key": "2_CR131", "unstructured": "Easterbrook M. Clinical characteristics of hydroxychloroquine retinopathy. Evid Based ophthalmol. 2011;12:132–3.", "volume": "12", "year": "2011" }, { "DOI": "10.1016/S0161-6420(03)00409-3", "author": "I Mavrikakis", "doi-asserted-by": "crossref", "first-page": "1321", "journal-title": "Ophthalmology", "key": "2_CR132", "unstructured": "Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine—a reappraisal. Ophthalmology. 2003;110:1321–6.", "volume": "110", "year": "2003" }, { "DOI": "10.1136/bmj.1.5482.270", "author": "GB Arden", "doi-asserted-by": "crossref", "first-page": "270", "journal-title": "Br Med J", "key": "2_CR133", "unstructured": "Arden GB, Kolb H. Antimalarial therapy and early retinal changes in patients with rheumatoid arthritis. Br Med J. 1966;1:270–3.", "volume": "1", "year": "1966" }, { "author": "DS Finbloom", "first-page": "692", "journal-title": "J Rheumatol", "key": "2_CR134", "unstructured": "Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol. 1985;12:692–4.", "volume": "12", "year": "1985" }, { "author": "A Savarino", "first-page": "67", "journal-title": "Reflection React", "key": "2_CR135", "unstructured": "Savarino A, Trani LD, Donateli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Reflection React. 2006;6:67–8.", "volume": "6", "year": "2006" }, { "DOI": "10.1016/0002-9394(68)91300-7", "author": "RE Carr", "doi-asserted-by": "crossref", "first-page": "738", "journal-title": "Am J Ophthalmol", "key": "2_CR136", "unstructured": "Carr RE, Henkind P, Rothfield N, Siegel IM. Ocular toxicity of antimalarial drugs-long-term follow-up. Am J Ophthalmol. 1968;66:738–44.", "volume": "66", "year": "1968" }, { "DOI": "10.1136/bmj.3.5618.579", "author": "SPB Percival", "doi-asserted-by": "crossref", "first-page": "579", "journal-title": "Br Med J", "key": "2_CR137", "unstructured": "Percival SPB, Meanock I. Chloroquine: ophthalmological safety and clinical assessment in rheumatoid arthritis. Br Med J. 1968;3:579–84.", "volume": "3", "year": "1968" }, { "DOI": "10.1002/art.1780300512", "author": "DR Miller", "doi-asserted-by": "crossref", "first-page": "567", "journal-title": "Arthritis Rheum", "key": "2_CR138", "unstructured": "Miller DR, Fiechtner JJ, Carpenter JR, Brown RR, Stroshane RM, Stecher VJ. Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum. 1987;30:567–71.", "volume": "30", "year": "1987" }, { "DOI": "10.1016/0090-6980(85)90185-6", "author": "JG Kench", "doi-asserted-by": "crossref", "first-page": "199", "journal-title": "Prostaglandins", "key": "2_CR139", "unstructured": "Kench JG, Seale JP, Temple DM, Tennant C. The effects of non-steroidal inhibitors of phospholipase A2 on leukotriene and histamine release from human and guinea-pig lung. Prostaglandins. 1985;30:199–208.", "volume": "30", "year": "1985" }, { "author": "M Frisk-Holmberg", "first-page": "624P", "journal-title": "Br J Clin Pharmacol", "key": "2_CR140", "unstructured": "Frisk-Holmberg M, Bergqvist Y. Chloroquine disposition in man. Br J Clin Pharmacol. 1982;14:624P–6.", "volume": "14", "year": "1982" }, { "DOI": "10.1016/0002-9343(83)91266-4", "author": "G Salmeron", "doi-asserted-by": "crossref", "first-page": "19", "journal-title": "Am J Med", "key": "2_CR141", "unstructured": "Salmeron G, Lipsky PE. Immunosuppressive potential of antimalarials. Am J Med. 1983;75:19–24.", "volume": "75", "year": "1983" }, { "author": "SE Tett", "first-page": "1874", "journal-title": "J Rheumatol", "key": "2_CR142", "unstructured": "Tett SE, Day RO, Cutler DJ. Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis—a cross sectional study. J Rheumatol. 1993;20:1874–9.", "volume": "20", "year": "1993" }, { "DOI": "10.3109/03009747809095649", "author": "FA Wollheim", "doi-asserted-by": "crossref", "first-page": "171", "journal-title": "Scand J Rheumatol", "key": "2_CR143", "unstructured": "Wollheim FA, Hanson A, Laurell CB. Chloroquine treatment in rheumatoid arthritis. Scand J Rheumatol. 1978;7:171–6.", "volume": "7", "year": "1978" }, { "DOI": "10.1002/art.22156", "author": "N Costedoat-Chalumeau", "doi-asserted-by": "crossref", "first-page": "3284", "journal-title": "Arthritis Rheum", "key": "2_CR144", "unstructured": "Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hummoud HA, Aymard G, Cacoub P, Frances C, Wechsler B, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;65:3284–90.", "volume": "65", "year": "2006" }, { "DOI": "10.1038/2271257a0", "author": "S Ullberg", "doi-asserted-by": "crossref", "first-page": "1257", "journal-title": "Nature", "key": "2_CR145", "unstructured": "Ullberg S, Lindquist NG, Sjostrand SE. Accumulation of chorio-retinotoxic drugs in the foetal eye. Nature. 1970;227:1257–8.", "volume": "227", "year": "1970" }, { "DOI": "10.1002/art.20648", "author": "R Cimaz", "doi-asserted-by": "crossref", "first-page": "3056", "journal-title": "Arthritis Rheum", "key": "2_CR146", "unstructured": "Cimaz R, Brucato A, Meregalli E, Muscara M, Sergi P. Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al. Arthritis Rheum. 2004;50:3056–7.", "volume": "50", "year": "2004" }, { "DOI": "10.1002/art.10150", "author": "N Costedoat-Chalumeau", "doi-asserted-by": "crossref", "first-page": "1123", "journal-title": "Arthritis Rheum", "key": "2_CR147", "unstructured": "Costedoat-Chalumeau N, Amoura Z, Aymard G, Hong DLT, Wechsler B, et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum. 2002;46:1123–4.", "volume": "46", "year": "2002" }, { "DOI": "10.1016/S0140-6736(01)06004-4", "author": "G Klinger", "doi-asserted-by": "crossref", "first-page": "813", "journal-title": "Lancet", "key": "2_CR148", "unstructured": "Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, Buncic RJ. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet. 2001;358:813–4.", "volume": "358", "year": "2001" }, { "DOI": "10.1016/S0140-6736(02)07643-2", "author": "M Motta", "doi-asserted-by": "crossref", "first-page": "524", "journal-title": "Lancet", "key": "2_CR149", "unstructured": "Motta M, Tincani A, Faden D, Zinzini E, Chirico G. Antimalarial agents in pregnancy. Lancet. 2002;359:524–5.", "volume": "359", "year": "2002" }, { "author": "A Parke", "first-page": "1715", "journal-title": "J Clin Rheumatol", "key": "2_CR150", "unstructured": "Parke A, West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Clin Rheumatol. 1996;23:1715–8.", "volume": "23", "year": "1996" }, { "DOI": "10.1002/art.22159", "author": "MEB Clowse", "doi-asserted-by": "crossref", "first-page": "3640", "journal-title": "Arthritis Rheum", "key": "2_CR151", "unstructured": "Clowse MEB, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54:3640–7.", "volume": "54", "year": "2006" }, { "DOI": "10.1177/0961203396005001141", "author": "MA Khamashta", "doi-asserted-by": "crossref", "first-page": "S65", "journal-title": "Lupus", "key": "2_CR152", "unstructured": "Khamashta MA, Buchanan NMM, Hughes GRV. The use of hydroxychloroquine in lupus pregnancy: the British experience. Lupus. 1996;5:S65–6.", "volume": "5", "year": "1996" }, { "DOI": "10.1002/art.11304", "author": "N Costedoat-Chalumeau", "doi-asserted-by": "crossref", "first-page": "3207", "journal-title": "Arthritis Rheum", "key": "2_CR153", "unstructured": "Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DLT, Sebbough D, Wechsler B, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue disease: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003;48:3207–11.", "volume": "48", "year": "2003" }, { "DOI": "10.2165/00002018-200124140-00004", "author": "MB Borden", "doi-asserted-by": "crossref", "first-page": "1055", "journal-title": "Drug Saf", "key": "2_CR154", "unstructured": "Borden MB, Parke AL. Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf. 2001;24:1055–83.", "volume": "24", "year": "2001" }, { "DOI": "10.1016/0002-9343(88)90359-2", "author": "A Parke", "doi-asserted-by": "crossref", "first-page": "30", "journal-title": "Am J Med", "key": "2_CR155", "unstructured": "Parke A. Antimalarial drugs and pregnancy. Am J Med. 1988;85:30–3.", "volume": "85", "year": "1988" }, { "DOI": "10.1001/archotol.1964.00750040419009", "author": "CW Hart", "doi-asserted-by": "crossref", "first-page": "407", "journal-title": "Arch Otolaryngol", "key": "2_CR156", "unstructured": "Hart CW, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol. 1964;80:407–12.", "volume": "80", "year": "1964" }, { "DOI": "10.1002/art.20649", "author": "N Costedoat-Chalumeau", "doi-asserted-by": "crossref", "first-page": "3057", "journal-title": "Arthritis Rheum", "key": "2_CR157", "unstructured": "Costedoat-Chalumeau N, Amoura Z, Sebbough D, Piette JC. Reply. Arthritis Rheum. 2004;50:3057–8.", "volume": "50", "year": "2004" }, { "DOI": "10.1007/BF00543338", "author": "M Ostensen", "doi-asserted-by": "crossref", "first-page": "357", "journal-title": "Eur J Clin Pharmacol", "key": "2_CR158", "unstructured": "Ostensen M, Brown ND, Chiang PK, Aarbakke J. Hydroxychloroquine in human breast milk. Eur J Clin Pharmacol. 1985;28:357.", "volume": "28", "year": "1985" }, { "author": "JCS Yam", "first-page": "294", "journal-title": "Hong Kong Med J", "key": "2_CR159", "unstructured": "Yam JCS, Kwok AKH. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006;12:294–304.", "volume": "12", "year": "2006" }, { "DOI": "10.1167/iovs.10-5278", "author": "YH Yoon", "doi-asserted-by": "crossref", "first-page": "6030", "journal-title": "Invest Ophthalmol Vis Sci", "key": "2_CR160", "unstructured": "Yoon YH, Cho KS, Hwang JJ, et al. Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. Invest Ophthalmol Vis Sci. 2010;51:6030–7.", "volume": "51", "year": "2010" }, { "DOI": "10.1016/0006-2952(74)90174-9", "author": "C Duve de", "doi-asserted-by": "crossref", "first-page": "2495", "journal-title": "Biochem Pharmacol", "key": "2_CR161", "unstructured": "de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. Lysosomotropic agents. Biochem Pharmacol. 1974;23:2495–531.", "volume": "23", "year": "1974" }, { "DOI": "10.1073/pnas.75.7.3327", "author": "S Ohkuma", "doi-asserted-by": "crossref", "first-page": "3327", "journal-title": "Proc Natl Acad Sci U S A", "key": "2_CR162", "unstructured": "Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A. 1978;75:3327–33.", "volume": "75", "year": "1978" }, { "DOI": "10.1016/0006-2952(87)90038-4", "author": "H Ginsburg", "doi-asserted-by": "crossref", "first-page": "1567", "journal-title": "Biochem Pharmacol", "key": "2_CR163", "unstructured": "Ginsburg H, Geary TG. Current concepts and new ideas on the mechanism of action of quinoline-containing antimalarials. Biochem Pharmacol. 1987;36:1567–76.", "volume": "36", "year": "1987" }, { "DOI": "10.1038/ncprheum0292", "author": "D Kyburz", "doi-asserted-by": "crossref", "first-page": "458", "journal-title": "Nat Clin Pract Rheumatol", "key": "2_CR164", "unstructured": "Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA—evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol. 2006;2:458–9.", "volume": "2", "year": "2006" }, { "DOI": "10.1016/0014-4886(81)90090-X", "author": "WT Stauber", "doi-asserted-by": "crossref", "first-page": "295", "journal-title": "Exp Neurol", "key": "2_CR165", "unstructured": "Stauber WT, Hedge AM, Trout JJ, Schottelius BA. Inhibition of lysosomal function in red and white skeletal muscles by chloroquine. Exp Neurol. 1981;71:295–306.", "volume": "71", "year": "1981" }, { "DOI": "10.1002/art.22157", "author": "R Lafyatis", "doi-asserted-by": "crossref", "first-page": "3068", "journal-title": "Arthritis Rheum", "key": "2_CR166", "unstructured": "Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on toll-like receptors? Arthritis Rheum. 2006;54:3068–70.", "volume": "54", "year": "2006" }, { "DOI": "10.1083/jcb.85.3.839", "author": "A Gonzalez-Noriega", "doi-asserted-by": "crossref", "first-page": "839", "journal-title": "J Cell Biol", "key": "2_CR167", "unstructured": "Gonzalez-Noriega A, Grubb JH, Talkad V, Sly WS. Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. J Cell Biol. 1980;85:839–52.", "volume": "85", "year": "1980" }, { "DOI": "10.1136/ard.43.5.710", "author": "CJP Jones", "doi-asserted-by": "crossref", "first-page": "710", "journal-title": "Ann Rheum Dis", "key": "2_CR168", "unstructured": "Jones CJP, Salisbury RS, Jayson MIV. The presence of abnormal lysosomes in lumphocytes and neutrophils during chloroquine therapy: a quantitative ultrastructural study. Ann Rheum Dis. 1984;43:710–5.", "volume": "43", "year": "1984" }, { "DOI": "10.1016/0049-3848(82)90241-9", "author": "C Prowse", "doi-asserted-by": "crossref", "first-page": "219", "journal-title": "Thromb Res", "key": "2_CR169", "unstructured": "Prowse C, Pepper D, Dawes J. Prevention of the platelet alpha-granule release reaction by membrane-active drugs. Thromb Res. 1982;25:219–27.", "volume": "25", "year": "1982" }, { "DOI": "10.6061/clinics/2013(06)07", "author": "J Cruz da Silva", "doi-asserted-by": "crossref", "first-page": "766", "journal-title": "Clinics", "key": "2_CR170", "unstructured": "Cruz da Silva J, Mariz HA, da Rocha Jr LF, de Oliveira PSS, Dantas AT, Duarte ALBP, Pitta IDR, Galdino SL, Pitta MGDR. Hydroxychloroquine decreases TH17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics. 2013;68:766–71.", "volume": "68", "year": "2013" }, { "DOI": "10.1111/j.1768-322X.1985.tb00408.x", "author": "JC Antoine", "doi-asserted-by": "crossref", "first-page": "41", "journal-title": "Biol Cell", "key": "2_CR171", "unstructured": "Antoine JC, Gould B, Jovanne C, Maurice M, Feldman G. Ammonium chloride, methylamine and chloroquine reversibly inhibit antibody secretion by plasma cells. Biol Cell. 1985;55:41–54.", "volume": "55", "year": "1985" }, { "DOI": "10.4049/jimmunol.160.3.1122", "author": "DE Macfarlane", "doi-asserted-by": "crossref", "first-page": "1122", "journal-title": "J Immunol", "key": "2_CR172", "unstructured": "Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol. 1998;160:1122–31.", "volume": "160", "year": "1998" }, { "DOI": "10.1001/archopht.1964.00970010568022", "author": "DG McConnell", "doi-asserted-by": "crossref", "first-page": "552", "journal-title": "Arch Ophthalmol", "key": "2_CR173", "unstructured": "McConnell DG, Wachtel J, Havener WH. Observations on experimental chloroquine retinopathy. Arch Ophthalmol. 1964;71:552–3.", "volume": "71", "year": "1964" }, { "DOI": "10.1177/0961203308097574", "author": "MR Namazi", "doi-asserted-by": "crossref", "first-page": "104", "journal-title": "Lupus", "key": "2_CR174", "unstructured": "Namazi MR. The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquinere and hydroxychloroquine. Lupus. 2009;18:104–5.", "volume": "18", "year": "2009" }, { "DOI": "10.1016/S0306-3623(97)00269-3", "author": "J Bondeson", "doi-asserted-by": "crossref", "first-page": "357", "journal-title": "Gen Pharmacol", "key": "2_CR175", "unstructured": "Bondeson J, Sundler R. Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1 beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis. Gen Pharmacol. 1998;30:357–66.", "volume": "30", "year": "1998" }, { "DOI": "10.1016/S0378-4347(00)86059-4", "author": "G Alvan", "doi-asserted-by": "crossref", "first-page": "241", "journal-title": "J Chromatogr", "key": "2_CR176", "unstructured": "Alvan G. Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromotography. J Chromatogr. 1982;229:241–7.", "volume": "229", "year": "1982" }, { "DOI": "10.1016/0008-8749(87)90043-8", "author": "VM Sanders", "doi-asserted-by": "crossref", "first-page": "419", "journal-title": "Cell Immunol", "key": "2_CR177", "unstructured": "Sanders VM, Uhr JW, Vitetta ES. Antigen-specific memory and virgin B cells differ in their requirements for conjugation to T cells. Cell Immunol. 1987;104:419–25.", "volume": "104", "year": "1987" }, { "DOI": "10.1038/214937a0", "author": "PB Macomber", "doi-asserted-by": "crossref", "first-page": "937", "journal-title": "Nature", "key": "2_CR178", "unstructured": "Macomber PB, Sprinz H. Morphological effects of chloroquine on Plasmodium berghei in mice. Nature. 1967;214:937–9.", "volume": "214", "year": "1967" }, { "DOI": "10.1126/science.1175667", "author": "RE Martin", "doi-asserted-by": "crossref", "first-page": "1680", "journal-title": "Science", "key": "2_CR179", "unstructured": "Martin RE, Marchetti RV, Cowen AI, Howitt SM, Broer SV, Kirk K. Chloroquine transport via the malaria parasite’s chloroquine resistance transporter. Science. 2009;325:1680–2.", "volume": "325", "year": "2009" }, { "author": "I Karres", "first-page": "R1058", "journal-title": "Am J Physiol", "key": "2_CR180", "unstructured": "Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol. 1998;274:R1058–64.", "volume": "274", "year": "1998" }, { "DOI": "10.1093/rheumatology/kei282", "author": "CH Jang", "doi-asserted-by": "crossref", "first-page": "703", "journal-title": "Rheumatology", "key": "2_CR181", "unstructured": "Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-alpha, IL-1 beta, and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology. 2006;45:703–10.", "volume": "45", "year": "2006" }, { "DOI": "10.4049/jimmunol.165.3.1534", "author": "SM Weber", "doi-asserted-by": "crossref", "first-page": "1534", "journal-title": "J Immunol", "key": "2_CR182", "unstructured": "Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-α gene expression by a nonlysosomotropic mechanism. J Immunol. 2000;165:1534–40.", "volume": "165", "year": "2000" }, { "DOI": "10.1016/S0140-6736(76)91090-4", "author": "MS Manku", "doi-asserted-by": "crossref", "first-page": "1115", "journal-title": "Lancet", "key": "2_CR183", "unstructured": "Manku MS, Horrobin DF. Chloroquine, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists. Lancet. 1976;20:1115–7.", "volume": "20", "year": "1976" }, { "DOI": "10.1016/0005-2760(85)90114-6", "author": "BM Loffler", "doi-asserted-by": "crossref", "first-page": "448", "journal-title": "Biochim Biophys Acta.", "key": "2_CR184", "unstructured": "Loffler BM, Bohn E, Hesse B, Kunze H. Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver. Biochim Biophys Acta. 1985;835:448–55.", "volume": "835", "year": "1985" }, { "DOI": "10.1016/0005-2760(80)90151-4", "author": "Y Matsuzawa", "doi-asserted-by": "crossref", "first-page": "592", "journal-title": "Biochim Biophys Acta.", "key": "2_CR185", "unstructured": "Matsuzawa Y, Hostetler KY. Effects of chloroquine and 4,4′-bis (diethylaminoethoxy)á, â-diethyldiphenylethane on the incorporation of [3H]glycerol into the phospholipids of rat liver lysosomes and other subcellular fractions, in vivo. Biochim Biophys Acta. 1980;620:592–602.", "volume": "620", "year": "1980" }, { "DOI": "10.1016/0040-8166(81)90013-6", "author": "JJ Trout", "doi-asserted-by": "crossref", "first-page": "393", "journal-title": "Tissue Cell.", "key": "2_CR186", "unstructured": "Trout JJ, Stauber WT, Schottelius BA. Increased autophagy in chloroquine treated tonic and phasic muscles: an alternative view. Tissue Cell. 1982;13:393–401.", "volume": "13", "year": "1982" }, { "DOI": "10.1038/213628a0", "author": "R Fiddick", "doi-asserted-by": "crossref", "first-page": "628", "journal-title": "Nature", "key": "2_CR187", "unstructured": "Fiddick R, Heath H. Inhibition of alcohol dehydrogenase by chloroquine. Nature. 1967;213:628–9.", "volume": "213", "year": "1967" }, { "DOI": "10.1016/0006-2952(72)90350-4", "author": "R Roskoski Jr", "doi-asserted-by": "crossref", "first-page": "391", "journal-title": "Biochem Pharmacol", "key": "2_CR188", "unstructured": "Roskoski Jr R, Jaskunas SR. Chloroquine and primaquine inhibition of rat liver cell-free polynucleotide-dependent polypeptide synthesis. Biochem Pharmacol. 1972;21:391–9.", "volume": "21", "year": "1972" }, { "DOI": "10.1016/0006-2952(73)90403-6", "author": "CF Lefler", "doi-asserted-by": "crossref", "first-page": "715", "journal-title": "Biochem Pharmacol", "key": "2_CR189", "unstructured": "Lefler CF, Lilja HS, Holbrook Jr DJ. Inhibition of aminoacylation and polypeptide synthesis by chloroquine and primaquine in rat liver in vitro. Biochem Pharmacol. 1973;22:715–28.", "volume": "22", "year": "1973" }, { "DOI": "10.1084/jem.124.2.209", "author": "PA Ward", "doi-asserted-by": "crossref", "first-page": "209", "journal-title": "J Exp Med", "key": "2_CR190", "unstructured": "Ward PA. The chemosuppression of chemotaxis. J Exp Med. 1966;124:209–26.", "volume": "124", "year": "1966" }, { "DOI": "10.1128/AAC.32.8.1124", "author": "MT Labro", "doi-asserted-by": "crossref", "first-page": "1124", "journal-title": "Antimicrob Agents Chemother", "key": "2_CR191", "unstructured": "Labro MT, Babin-Chevaye C. Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro. Antimicrob Agents Chemother. 1988;32:1124–30.", "volume": "32", "year": "1988" }, { "DOI": "10.1056/NEJM196511182732107", "author": "G Weissmann", "doi-asserted-by": "crossref", "first-page": "1143", "journal-title": "New Engl J Med", "key": "2_CR192", "unstructured": "Weissmann G. Lysosomes (concluded). New Engl J Med. 1965;273:1143–9.", "volume": "273", "year": "1965" }, { "DOI": "10.1002/art.21273", "author": "F Brentano", "doi-asserted-by": "crossref", "first-page": "2656", "journal-title": "Arthritis Rheum", "key": "2_CR193", "unstructured": "Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum. 2005;52:2656–65.", "volume": "52", "year": "2005" }, { "DOI": "10.1038/416603a", "author": "EA Leadbetter", "doi-asserted-by": "crossref", "first-page": "603", "journal-title": "Nature", "key": "2_CR194", "unstructured": "Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Schlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002;416:603–7.", "volume": "416", "year": "2002" }, { "DOI": "10.1080/08820530802049962", "author": "R Tehrani", "doi-asserted-by": "crossref", "first-page": "201", "journal-title": "Semin Ophthalmol", "key": "2_CR195", "unstructured": "Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophthalmol. 2008;23:201–9.", "volume": "23", "year": "2008" }, { "DOI": "10.1016/0006-2952(83)90267-8", "author": "A Wada", "doi-asserted-by": "crossref", "first-page": "1175", "journal-title": "Biochem Pharmacol", "key": "2_CR196", "unstructured": "Wada A, Sakurai S, Kobayashi H, Yanagihara N, Izumi F. Suppression by phospholipase A2 inhibitors of secretion of catecholamines from isolated adrenal medullary cells by suppression of cellular calcium uptake. Biochem Pharmacol. 1983;32:1175–8.", "volume": "32", "year": "1983" }, { "DOI": "10.1016/0006-291X(75)90506-9", "author": "EN Wiesmann", "doi-asserted-by": "crossref", "first-page": "1338", "journal-title": "Biochem Biophys Res Commun.", "key": "2_CR197", "unstructured": "Wiesmann EN, DiDonato S, Herschkowitz NN. Effect of chloroquine on cultured fibroblasts: release of lysosomal hydrolases and inhibition of their uptake. Biochem Biophys Res Commun. 1975;66:1338–43.", "volume": "66", "year": "1975" }, { "DOI": "10.1056/NEJMoa035471", "author": "MJ Roman", "doi-asserted-by": "crossref", "first-page": "2299", "journal-title": "N Engl J Med.", "key": "2_CR198", "unstructured": "Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2299–406.", "volume": "349", "year": "2003" }, { "DOI": "10.1016/0002-9343(90)90345-E", "author": "DJ Wallace", "doi-asserted-by": "crossref", "first-page": "322", "journal-title": "Am J Med", "key": "2_CR199", "unstructured": "Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med. 1990;89:322–6.", "volume": "89", "year": "1990" }, { "DOI": "10.1001/jama.298.2.187", "author": "MCM Wasko", "doi-asserted-by": "crossref", "first-page": "187", "journal-title": "JAMA", "key": "2_CR200", "unstructured": "Wasko MCM, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward MM. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298:187–93.", "volume": "298", "year": "2007" }, { "DOI": "10.1136/bmj.294.6576.900-c", "doi-asserted-by": "crossref", "key": "2_CR224", "unstructured": "Kitridou R, Rees RG, Smith MJ, Peiris A, Kissebah AH. Effect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non-insulin dependent diabetes mellitus. Br Med J. 1987;294:900–1." }, { "DOI": "10.1177/0961203306071872", "author": "G Ruiz-Irastorza", "doi-asserted-by": "crossref", "first-page": "577", "journal-title": "Lupus", "key": "2_CR201", "unstructured": "Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, Erdozain JG, Aguirre C. Effects of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577–83.", "volume": "15", "year": "2006" }, { "DOI": "10.1056/NEJM196507012730105", "author": "D Hurvitz", "doi-asserted-by": "crossref", "first-page": "23", "journal-title": "N Engl J Med.", "key": "2_CR202", "unstructured": "Hurvitz D, Hirschhorn K. Suppression of in vitro lymphocyte responses by chloroquine. N Engl J Med. 1965;273:23–6.", "volume": "273", "year": "1965" }, { "DOI": "10.1083/jcb.102.3.959", "author": "S Ohkuma", "doi-asserted-by": "crossref", "first-page": "959", "journal-title": "J Cell Biol", "key": "2_CR203", "unstructured": "Ohkuma S, Chudzik J, Poole B. The effects of basic substances and acidic ionophores on the digestion of exogenous and endogenous proteins in mouse peritoneal macrophages. J Cell Biol. 1986;102:959–66.", "volume": "102", "year": "1986" }, { "author": "K Oda", "first-page": "739", "journal-title": "J Biol Chem", "key": "2_CR204", "unstructured": "Oda K, Koriyama Y, Yamada E, Ikehara Y. Effects of weakly basic amines on proteolytic processing and terminal glycosylation of secretory proteins in cultured rat hepatocytes. J Biol Chem. 1986;240:739–45.", "volume": "240", "year": "1986" }, { "key": "2_CR205", "unstructured": "Wright CI, Sabine JC. Cholinesterases of human erythrocytes and plasma and their inhibition by antimalarial drugs. J Pharmacol Exp Ther. 1948;93:230–9." }, { "DOI": "10.1046/j.0019-2805.2001.01339.x", "author": "JY Jeong", "doi-asserted-by": "crossref", "first-page": "83", "journal-title": "Immunology", "key": "2_CR206", "unstructured": "Jeong JY, Choi JW, Jeon KI, Jue DM. Chloroquine decreases cell-surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology. 2002;105:83–91.", "volume": "105", "year": "2002" }, { "DOI": "10.1002/art.1780400522", "author": "XW Meng", "doi-asserted-by": "crossref", "first-page": "927", "journal-title": "Arthritis Rheum", "key": "2_CR207", "unstructured": "Meng XW, Feller JM, Ziegler JB, Pittman SM, Ireland CM. Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum. 1997;40:927–35.", "volume": "40", "year": "1997" }, { "DOI": "10.1111/j.1365-2249.2006.03070.x", "author": "WU Kim", "doi-asserted-by": "crossref", "first-page": "503", "journal-title": "Clin Exp Immunol", "key": "2_CR208", "unstructured": "Kim WU, Yoo SA, Min SY, Park SH, Koh HS, Song SW, Cho CS. Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. Clin Exp Immunol. 2006;144:503–11.", "volume": "144", "year": "2006" }, { "DOI": "10.4049/jimmunol.168.10.5303", "author": "SM Weber", "doi-asserted-by": "crossref", "first-page": "5303", "journal-title": "J Immunol", "key": "2_CR209", "unstructured": "Weber SM, Chen JM, Levitz SM. Inhibition of mitogen-activated protein kinase signaling by chloroquine. J Immunol. 2002;168:5303–9.", "volume": "168", "year": "2002" }, { "DOI": "10.1172/JCI1052", "author": "D Ghigo", "doi-asserted-by": "crossref", "first-page": "595", "journal-title": "J Clin Invest", "key": "2_CR210", "unstructured": "Ghigo D, Aldieri E, Todde R, Costamagna C, Garbarino G, Pescarmona G, Bosia A. Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells. J Clin Invest. 1998;102:595–605.", "volume": "102", "year": "1998" }, { "DOI": "10.1016/S0006-291X(80)80237-3", "author": "C Tietze", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "Biochem Biophys Res Commun.", "key": "2_CR211", "unstructured": "Tietze C, Schlesinger P, Stahl P. Chloroquine and ammonium ion inhibit receptor-mediated endocystosis of mannose-glyconjugates by macrophages: apparent inhibition of receptor recycling. Biochem Biophys Res Commun. 1980;93:1–8.", "volume": "93", "year": "1980" }, { "DOI": "10.1126/science.149.3688.1111", "doi-asserted-by": "crossref", "key": "2_CR225", "unstructured": "Allison JL, O’Brien RL, Hahn FE. DNA: reaction with chloroquine. Science. 1965;149:1111–3." }, { "DOI": "10.1126/science.151.3708.347", "author": "J Ciak", "doi-asserted-by": "crossref", "first-page": "347", "journal-title": "Science", "key": "2_CR212", "unstructured": "Ciak J, Hahn FE. Chloroquine: mode of action. Science. 1966;151:347–9.", "volume": "151", "year": "1966" }, { "DOI": "10.1073/pnas.55.6.1511", "doi-asserted-by": "crossref", "key": "2_CR213", "unstructured": "O’Brien RL, Olenick JG, Hahn FE. Reactions of quinine, chloroquine, and quinacrine with DNA and their effects on the DNA and RNA polymerase reactions. Proc Natl Acad Sci USA. 1966;55:1511–7." }, { "DOI": "10.1007/BF02890416", "author": "T Yucel-Lindberg", "doi-asserted-by": "crossref", "first-page": "141", "journal-title": "Virchows Arch B Cell Pathol.", "key": "2_CR214", "unstructured": "Yucel-Lindberg T, Jansson H, Glaumann H. Proteolysis in isolated autophagic vacuoles from the rat pancreas. Effects of chloroquine administration. Virchows Arch B Cell Pathol. 1991;61:141–5.", "volume": "61", "year": "1991" }, { "author": "MF Raines", "first-page": "1726", "journal-title": "Invest Ophthalmol Vis Sci", "key": "2_CR215", "unstructured": "Raines MF, Bhargava SK, Rosen ES. The blood-retinal barrier in chloroquine retinopathy. Invest Ophthalmol Vis Sci. 1989;30:1726–31.", "volume": "30", "year": "1989" }, { "DOI": "10.1111/j.1444-0938.2000.tb05072.x", "author": "HS Weisinger", "doi-asserted-by": "crossref", "first-page": "32", "journal-title": "Clin Exp Optom", "key": "2_CR216", "unstructured": "Weisinger HS, Pesudovs K, Collin HB. Management of patients undergoing hydroxychloroquine (Plaquenil) therapy. Clin Exp Optom. 2000;83:32–6.", "volume": "83", "year": "2000" }, { "DOI": "10.1016/S0021-9258(19)40894-6", "author": "JL Goldstein", "doi-asserted-by": "crossref", "first-page": "7854", "journal-title": "J Biol Chem", "key": "2_CR217", "unstructured": "Goldstein JL, Brunschede GY, Brown MS. Inhibition of the proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and Triton WR 1339. J Biol Chem. 1975;250:7854–62.", "volume": "250", "year": "1975" }, { "author": "CM Ausiello", "first-page": "255", "journal-title": "Clin Exp Rheumatol", "key": "2_CR218", "unstructured": "Ausiello CM, Barbieri P, Spagnoli GC, Ciompi ML, Gasciani CU. In vivo effects of chloroquine treatment on spontaneous and interferon-induced natural killer activities in rheumatoid arthritis patients. Clin Exp Rheumatol. 1986;4:255–9.", "volume": "4", "year": "1986" }, { "DOI": "10.1016/0005-2787(66)90078-5", "author": "RL O’Brien", "doi-asserted-by": "crossref", "first-page": "622", "journal-title": "Biochim Biophys Acta", "key": "2_CR219", "unstructured": "O’Brien RL, Allison JL, Hahn FE. Evidence for intercalation of chloroquine into DNA. Biochim Biophys Acta. 1966;129:622–4.", "volume": "129", "year": "1966" }, { "author": "A Wozniacka", "first-page": "1124", "journal-title": "Br J Dermatol", "key": "2_CR220", "unstructured": "Wozniacka A, Lesiak A, Boncela J, Smolarczyk K, McCauliffe DP, Sysa-Jedrzejowska A. The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br J Dermatol. 2008;159:1124–30.", "volume": "159", "year": "2008" }, { "DOI": "10.1124/jpet.102.042523", "author": "MH Ahmed", "doi-asserted-by": "crossref", "first-page": "156", "journal-title": "J Pharmacol Exp Ther", "key": "2_CR221", "unstructured": "Ahmed MH, Ashton N, Balment RJ. The effect of chloroquine on renal function and vasopressin secretion: a nitric oxide-dependent effect. J Pharmacol Exp Ther. 2003;304:156–61.", "volume": "304", "year": "2003" }, { "DOI": "10.1084/jem.20051106", "author": "D Accapezzato", "doi-asserted-by": "crossref", "first-page": "817", "journal-title": "J Exp Med", "key": "2_CR222", "unstructured": "Accapezzato D, Visco V, Francavilla V, Molette C, Donato T, et al. Chloroquine enhances human CD8 T cell responses against soluble antigens in vivo. J Exp Med. 2005;202:817–28.", "volume": "202", "year": "2005" } ], "reference-count": 225, "references-count": 225, "relation": {}, "resource": { "primary": { "URL": "http://link.springer.com/10.1007/978-1-4939-0597-3_2" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Pharmacology of Chloroquine and Hydroxychloroquine", "type": "book-chapter", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy" }

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0